You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
|
|---|---|
| Published in |
Blood Advances, May 2019
|
| DOI | 10.1182/bloodadvances.2018030007 |
| Pubmed ID | |
| Authors |
Farrukh T Awan, Anna Schuh, Jennifer R Brown, Richard R Furman, John M Pagel, Peter Hillmen, Deborah M Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C Byrd |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 26% |
| Spain | 3 | 16% |
| Brazil | 1 | 5% |
| China | 1 | 5% |
| Canada | 1 | 5% |
| Japan | 1 | 5% |
| Korea, Democratic People's Republic of | 1 | 5% |
| Unknown | 6 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 68% |
| Scientists | 3 | 16% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
| Unknown | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 130 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 18% |
| Other | 16 | 12% |
| Student > Doctoral Student | 9 | 7% |
| Student > Ph. D. Student | 8 | 6% |
| Student > Bachelor | 6 | 5% |
| Other | 21 | 16% |
| Unknown | 47 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 34% |
| Biochemistry, Genetics and Molecular Biology | 13 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Immunology and Microbiology | 3 | 2% |
| Chemistry | 2 | 2% |
| Other | 10 | 8% |
| Unknown | 50 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,007,096
of 25,123,315 outputs
Outputs from Blood Advances
#146
of 3,128 outputs
Outputs of similar age
#22,509
of 357,986 outputs
Outputs of similar age from Blood Advances
#5
of 102 outputs
Altmetric has tracked 25,123,315 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,128 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 357,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.